The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats

Analyzing real-time PCR data by the comparative CT method

Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190

Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis

Moreau, R., Jalan, R., Ginès, P., Pavesi, M., Angeli, P., Córdoba, J., Durand, F., Gustot, T., Saliba, F., Domenicali, M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.042 · Cited by 3,041

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870 · cited 2×

Tight Junction Pore and Leak Pathways: A Dynamic Duo

Shen, L., Weber, C. R., Raleigh, D. R., Yu, D., & Turner, J. R. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142150 · Cited by 867

Translocation of Certain Indigenous Bacteria from the Gastrointestinal Tract to the Mesenteric Lymph Nodes and Other Organs in a Gnotobiotic Mouse Model

Berg, R. D., & Garlington, A. W. (1979) · Infection and Immunity · doi:10.1128/iai.23.2.403-411.1979 · Cited by 845

Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers.

Madara, J. L., & Stafford, J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113938 · Cited by 758

6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity

Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743

Interferon-γ and Tumor Necrosis Factor-α Synergize to Induce Intestinal Epithelial Barrier Dysfunction by Up-Regulating Myosin Light Chain Kinase Expression

Wang, F., Graham, W. V., Wang, Y., Witkowski, E. D., Schwarz, B. T., & Turner, J. R. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62264-x · Cited by 692

Changes of Intestinal Functions in Liver Cirrhosis

Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,820

The gut-liver axis in liver disease: Pathophysiological basis for therapy

Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166

Gut-liver axis: Pathophysiological concepts and clinical implications

Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843

Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development

Mouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688

The gut microbiome and liver cancer: mechanisms and clinical translation

Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634

Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets

Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 615

Intestinal Barrier in Human Health and Disease

Tommaso, N. D., Gasbarrini, A., & Ponziani, F. R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312836 · Cited by 577

Molecular physiology of bile acid signaling in health, disease, and aging

Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481

Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH

Pierantonelli, I., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 473

Acute-on-chronic liver failure in cirrhosis

Arroyo, V., Moreau, R., Kamath, P. S., Jalan, R., Ginès, P., Nevens, F., Fernández, J., To, U. K., García–Tsao, G., & Schnabl, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.41 · Cited by 450

Targeting the gut-liver axis in liver disease

Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S., & Jalan, R. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.007 · Cited by 427

Bile acids as modulators of gut microbiota composition and function

Larabi, A. B., Masson, H. L. P., & Bäumler, A. J. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2172671 · Cited by 443

Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex

Rizzetto, L., Fava, F., Tuohy, K. M., & Selmi, C. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.05.008 · Cited by 331

The microbiota in cirrhosis and its role in hepatic decompensation

Trebicka, J., Macnaughtan, J., Schnabl, B., Shawcross, D. L., & Bajaj, J. S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.013 · Cited by 283

Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease

Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269

Microbiota, cirrhosis, and the emerging oral-gut-liver axis

Acharya, C., Sahingur, S. E., & Bajaj, J. S. (2017) · JCI Insight · doi:10.1172/jci.insight.94416 · Cited by 260

FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis

Sorribas, M., Jakob, M. O., Yılmaz, B., Li, H., Stutz, D., Noser, Y., Gottardi, A. D., Moghadamrad, S., Hassan, M., Albillos, A., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.017 · Cited by 258

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

Verbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., Mazzone, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33453 · Cited by 236

Bile acid metabolism and signalling in liver disease

Fuchs, C. D., Simbrunner, B., Baumgartner, M., Campbell, C., Reiberger, T., & Trauner, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.032 · Cited by 265

Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg

Arab, J. P., Martín‐Mateos, R., & Shah, V. H. (2017) · Hepatology International · doi:10.1007/s12072-017-9798-x · Cited by 233

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy

Iwakiri, Y., & Trebicka, J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100316 · Cited by 245

Antibiotic prophylaxis in cirrhosis: Good and bad

Fernández, J., Tandon, P., Mensa, J., & García–Tsao, G. (2015) · Hepatology · doi:10.1002/hep.28330 · Cited by 205

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

Hu, H., Lin, A., Kong, M., Yao, X., Yin, M., Xia, H., Ma, J., & Liu, H. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01649-8 · Cited by 211

Lactobacillus bile salt hydrolase substrate specificity governs bacterial fitness and host colonization

Foley, M. H., O’Flaherty, S., Allen, G., Rivera, A. J., Stewart, A. K., Barrangou, R., & Theriot, C. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017709118 · Cited by 205

Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure

Trebicka, J., Bork, P., Krag, A. A., & Arumugam, M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00376-3 · Cited by 204

Gut dysbiosis associated with hepatitis C virus infection

Inoue, T., Nakayama, J., Moriya, K., Kawaratani, H., Momoda, R., Ito, K., Iio, E., Nojiri, S., Fujiwara, K., Yoneda, M., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy205 · Cited by 183

Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats

Úbeda, M., Lario, M., Muñoz, L., Borrero, M.-J., Rodríguez-Serrano, M., Sánchez-Díaz, A.-M., del Campo, R., Lledó, L., Pastor, Ó., García-Bermejo, L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.12.010 · Cited by 178

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

Schwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.005 · Cited by 178

Acupuncture and regulation of gastrointestinal function

Li, H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i27.8304 · Cited by 167

Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?

Fukui, H. (2019) · Diseases · doi:10.3390/diseases7040058 · Cited by 159

FXR-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid

Friedman, E. S., Li, Y., Shen, T.-C. D., Jiang, J., Chau, L., Adorini, L., Babakhani, F., Edwards, J., Shapiro, D., Zhao, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.022 · Cited by 149

Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease

Suk, K. T., & Kim, D. J. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1569513 · Cited by 139

Breakthroughs in therapies for NASH and remaining challenges

Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132

Bile acid receptors and gastrointestinal functions

Ticho, A. L., Malhotra, P., Dudeja, P. K., Gill, R. K., & Alrefai, W. A. (2019) · Liver Research · doi:10.1016/j.livres.2019.01.001 · Cited by 138

Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation

Xiong, X., Ren, Y., Cui, Y., Li, R., Wang, C., & Zhang, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.083 · Cited by 125

Gut microbiome in primary sclerosing cholangitis: A review

Little, R., Wine, E., Kamath, B. M., Griffiths, A. M., & Ricciuto, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i21.2768 · Cited by 123

Bile acids and their receptors in regulation of gut health and diseases

Lin, S., Wang, S., Wang, P., Tang, C., Wang, Z., Chen, L., Luo, G., Chen, H., Liu, Y., Feng, B., et al. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101210 · Cited by 128

Role of bile acids in inflammatory liver diseases

Evangelakos, I., Heeren, J., Verkade, E., & Kuipers, F. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00869-6 · Cited by 121

Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update

Fukui, H. (2020) · Gut and Liver · doi:10.5009/gnl20032 · Cited by 121

Gut-liver axis signaling in portal hypertension

Simbrunner, B., Mandorfer, M., Trauner, M., & Reiberger, T. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i39.5897 · Cited by 113

Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis

Simbrunner, B., Trauner, M., & Reiberger, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16602 · Cited by 108

Gut microbiome and liver disease

Betrapally, N. S., Gillevet, P. M., & Bajaj, J. S. (2016) · Translational research · doi:10.1016/j.trsl.2016.07.005 · Cited by 106

The multifactorial mechanisms of bacterial infection in decompensated cirrhosis

der Merwe, V., Chokshi, S., Bernsmeier, C., & Albillos, A. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.029 · Cited by 102

Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects

Legry, V., Francque, S., Haas, J. T., Verrijken, A., Caron, S., Chávez‐Talavera, O., Vallez, E., Vonghia, L., Dirinck, E. L., Verhaegen, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01397 · Cited by 102

Critical roles of bile acids in regulating intestinal mucosal immune responses

Sun, R., Xu, C., Feng, B., Gao, X., & Liu, Z. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211018098 · Cited by 105

Infections in cirrhosis

Piano, S. S., Bunchorntavakul, C., Marciano, S., & Reddy, K. R. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00078-5 · Cited by 95

The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity

He, Y., Shaoyong, W., Chen, Y., Li, M., Gan, Y., Sun, L., Liu, Y., Wang, Y., & Jin, M. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.05.015 · Cited by 107

The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective

Wang, L., Cao, Z.-M., Zhang, L., Li, J.-M., & Lv, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923599 · Cited by 89

Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough

Laleman, W., Clària, J., der Merwe, V., Moreau, R., & Trebicka, J. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/1027152 · Cited by 84

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 83

The Pathophysiology of Farnesoid X Receptor (FXR) in the GI Tract: Inflammation, Barrier Function and Innate Immunity

Anderson, K. M., & Gayer, C. P. (2021) · Cells · doi:10.3390/cells10113206 · Cited by 82

Novel perspectives in the management of decompensated cirrhosis

Bernardi, M., & Caraceni, P. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0045-2 · Cited by 81

TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

Labiano, I., Agirre-Lizaso, A., Olaizola, P., Echebarria, A., Huici-Izagirre, M., Olaizola, I., Esparza-Baquer, A., Sharif, O., Hijona, E., Milkiewicz, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.044 · Cited by 78

Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation

Zhang, D.-G., Zhang, C., Wang, J., Wang, B.-W., Wang, H., Zhang, Z., Chen, Y., Lu, Y., Li, T., Wang, J., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.11.006 · Cited by 79

Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling

Meadows, V., Kennedy, L., Ekser, B., Kyritsi, K., Kundu, D., Zhou, T.-H., Chen, L.-X., Pham, L., Wu, N., Demieville, J., et al. (2021) · Hepatology · doi:10.1002/hep.32028 · Cited by 55

Bile acids and cardiovascular function in cirrhosis

Voiosu, A. M., Wiese, S. S., Voiosu, T. A., Bendtsen, F., & Møller, S. (2017) · Liver International · doi:10.1111/liv.13394 · Cited by 70

Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events

Gustot, T., Stadlbauer, V., Laleman, W., Alessandria, C., & Thursz, M. R. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.005 · Cited by 76

Gut Microbiota and Host Reaction in Liver Diseases

Fukui, H. (2015) · Microorganisms · doi:10.3390/microorganisms3040759 · Cited by 64

Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats

Ceulemans, L. J., Verbeke, L., Decuypere, J.-P., Farré, R., Hertogh, G. D., Lenaerts, K., Jochmans, I., Monbaliu, D. R. L., Nevens, F., Tack, J. F., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169331 · Cited by 63

Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation

Yang, F., Tang, X., Ding, L., Zhou, Y., Yang, Q., Gong, J., Wang, G., Wang, Z., & Yang, L. (2016) · Scientific Reports · doi:10.1038/srep33052 · Cited by 61

Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease

Baffy, G. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4903-5 · Cited by 64

Blood‐Bile Barrier: Morphology, Regulation, and Pathophysiology

Pradhan-Sundd, T., & Monga, S. P. (2019) · Gene Expression · doi:10.3727/105221619x15469715711907 · Cited by 54

Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction

Sauerbruch, T., Hennenberg, M., Trebicka, J., & Beuers, U. H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.718783 · Cited by 55

Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response

Simbrunner, B., Caparrós, E., Neuwirth, T., Schwabl, P., Königshofer, P., Bauer, D. J. M., Marculescu, R., Trauner, M. A., Scheiner, B., Stary, G., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10496-y · Cited by 51

Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases

Rodrigues, S. G., der Merwe, V., Krag, A. A., & Wiest, R. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2023.101859 · Cited by 51

Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases†

Nevens, F., Trauner, M., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 51

The gut microbiota-bile acid axis in cholestatic liver disease

Sun, D., Xie, C., Zhao, Y. M., Liao, J., Li, S., Zhang, Y., Wang, D., Hua, K., Gu, Y., Du, J., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00830-x · Cited by 56

Intestinal permeability in a patient with liver cirrhosis

Aguirre-Valádez, J., Rivera-Espinosa, L., Méndez-Guerrero, O., Chávez-Pacheco, J. L., Juárez, I. G., & Torre, A. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s115902 · Cited by 52

Pharmacologic prevention of variceal bleeding and rebleeding

Baiges, A., Hernández–Gea, V., & Bosch, J. (2017) · Hepatology International · doi:10.1007/s12072-017-9833-y · Cited by 49

Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer

Zhou, M., Wang, D., Li, X., Cao, Y., Yi, C., Ocansey, D. K. W., Zhou, Y., & Mao, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016836 · Cited by 49

Advances in intestinal epithelium and gut microbiota interaction

Yang, S., Liu, H., & Liu, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1499202 · Cited by 53

Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease

Simbrunner, B., Villesen, I. F., Königshofer, P., Scheiner, B., Bauer, D. J. M., Paternostro, R., Schwabl, P., Timelthaler, G., Ramazanova, D., Wöran, K., et al. (2022) · Liver International · doi:10.1111/liv.15365 · Cited by 47

Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis

Chen, J., Zheng, M., Liu, J., Luo, Y., Yang, W., Yang, J., Liu, J., Jingxing, Z., Xu, C., Zhao, F., et al. (2019) · Obesity · doi:10.1002/oby.22627 · Cited by 49

Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study

Hullar, M. A. J., Jenkins, I., Randolph, T. W., Curtis, K. R., Monroe, K. R., Ernst, T. M., Shepherd, J., Stram, D. O., Cheng, I. C., Kristal, B. S., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1965463 · Cited by 48

Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH

Hernandez, G. V., Smith, V. A., Melnyk, M., Burd, M. A., Sprayberry, K. A., Edwards, M. S., Peterson, D. G., Bennet, D. C., Fanter, R. K., Columbus, D. A., et al. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00344.2019 · Cited by 44

Interplay between Bile Acids and Intestinal Microbiota: Regulatory Mechanisms and Therapeutic Potential for Infections

Li, W., Chen, H., & Tang, J. (2024) · Pathogens · doi:10.3390/pathogens13080702 · Cited by 49

Oxidation of fish oil exacerbates alcoholic liver disease by enhancing intestinal dysbiosis in mice

Feng, R., Ma, L., Wang, M., Liu, C., Yang, R., Su, H., Yang, Y., & Wan, J. (2020) · Communications Biology · doi:10.1038/s42003-020-01213-8 · Cited by 45

Plasma Exchange in Acute and Acute on Chronic Liver Failure

Maiwall, R., & Sarin, S. K. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730971 · Cited by 47

Obeticholic Acid Protects against Lipopolysaccharide-Induced Fetal Death and Intrauterine Growth Restriction through Its Anti-Inflammatory Activity

Chen, Y., Hu, X., Zhou, Y., Yu, Z., Fu, L., Zhang, G.-B., Bo, Q., Wang, H., Zhang, C., & Xu, D. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601331 · Cited by 43

A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis

Xiao, Y., Wang, Y., Liu, Y., Wang, W., Tian, X., Chen, S., Lu, Y., Du, J., & Cai, W. (2021) · Liver International · doi:10.1111/liv.14906 · Cited by 43

Review of the Relationships Between Human Gut Microbiome, Diet, and Obesity

Patloka, O., Komprda, T., & Franke, G. (2024) · Nutrients · doi:10.3390/nu16233996 · Cited by 50

Pyrazinamide Induced Rat Cholestatic Liver Injury through Inhibition of FXR Regulatory Effect on Bile Acid Synthesis and Transport

Guo, H., Hassan, H. M., Zhang, Y., Dong, S.-Z., Ding, P., Wang, T., Sun, L., Zhang, L., & Jiang, Z. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw098 · Cited by 41

Intrahepatic cholestasis induced by α-naphthylisothiocyanate can cause gut-liver axis disorders

Chen, Z., Wu, Y., Wang, B., Fang, J., Gan, C., Sang, C., Dun, Z., Luosang, T., Wang, Q., Zeren, D., et al. (2021) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2021.103672 · Cited by 40

Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics

Cho, M. S., Kim, S. Y., Suk, K. T., & Kim, B. (2018) · The Journal of Microbiology · doi:10.1007/s12275-018-8346-2 · Cited by 42

Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease

Smeuninx, B., Boslem, E., & Febbraio, M. A. (2020) · Cancers · doi:10.3390/cancers12071714 · Cited by 39

A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development

Tang, Y., Fan, Y., Wang, Y., Wang, D., Huang, Q., Chen, T., Cao, X., Wen, C., Shen, X., Li, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116658 · Cited by 38

Dietary supplementation with tributyrin prevented weaned pigs from growth retardation and lethal infection via modulation of inflammatory cytokines production, ileal FGF19 expression, and intestinal acetate fermentation1

Gu, Y., Song, Y., Yin, H., Lin, S., Zhang, X., Che, L., Lin, Y., Xu, S., Feng, B., Wu, D., et al. (2017) · Journal of Animal Science · doi:10.2527/jas.2016.0911 · Cited by 41

Bile Formation and the Enterohepatic Circulation

Dawson, P. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00041-4 · Cited by 36

Controversies in the Mechanism of Total Parenteral Nutrition Induced Pathology

Kumar, J., & Teckman, J. H. (2015) · Children · doi:10.3390/children2030358 · Cited by 33

Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor

Tang, K., Kong, D., Peng, Y., Guo, J., Zhong, Y., Yu, H., Mai, Z., Chen, Y., Chen, Y., Cui, T., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1000444 · Cited by 33

Novel treatment options for portal hypertension

Schwabl, P., & Laleman, W. (2017) · Gastroenterology report · doi:10.1093/gastro/gox011 · Cited by 31

Metabolic-Associated Fatty Liver Disease and the Gut Microbiota

Barber, T. M., Hanson, P., & Weickert, M. O. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.004 · Cited by 31

Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR‐S1PR2 ‐dependent mechanism

Xu, W., Lu, C., Zhang, F., Shao, J., & Zheng, S. (2016) · IUBMB Life · doi:10.1002/iub.1492 · Cited by 31

Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota–Bile Acid–Immunity Network

Guo, Z., He, K., Pang, K., Yang, D., Lyu, C., Xu, H., & Wu, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084321 · Cited by 29

Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease

van Zutphen, T., Bertolini, A., de Vries, H. D., Bloks, V. W., de Boer, J. F., Jonker, J. W., & Kuipers, F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_233 · Cited by 31

Gut–Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers

Lombardi, M., Troisi, J., Motta, B. M., Torre, P., Masarone, M., & Persico, M. (2024) · Nutrients · doi:10.3390/nu16071025 · Cited by 27

Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer

Yin, Y., Wang, M., Gu, W., & Chen, L. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114430 · Cited by 27

Taurocholic acid, a primary 12α-hydroxylated bile acid, induces leakiness in the distal small intestine in rats

Liu, H., Kohmoto, O., Sakaguchi, A., Hori, S., Tochigi, M., Tada, K., Lee, Y., Kikuchi, K., & Ishizuka, S. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113136 · Cited by 27

Advances in the pharmacological management of bacterial peritonitis

Pörner, D., von Vietinghoff, S., Nattermann, J., Strassburg, C. P., & Lutz, P. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1915288 · Cited by 26

Novel prevention strategies for bacterial infections in cirrhosis

Yan, K. G., & García–Tsao, G. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1145663 · Cited by 26

Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction

Yan, M., Hou, L., Cai, Y., Wang, H., Ma, Y., Geng, Q., Jiang, W., & Tang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906452 · Cited by 25

Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats

Úbeda, M., Lario, M., Muñoz, L., Borrero, M.-J., Rodríguez-Serrano, M., Sánchez-Díaz, A.-M., del Campo, R., Lledó, L., Pastor, Ó., García-Bermejo, L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.12.010 · Cited by 178

Exploring the tissue specific roles of FXR within the gut-liver axis: Insights from a novel mouse model

Ludwigs, L., Reul, T., Henniges, A., Volkert, I., Peltzer, M., Becker, S., Molinario, A., Marshall, H.-U., Edlund, K., Hengstler, J. G., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-1777487

FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease

Koelfat, K. V. K., Visschers, R. G. J., Hodin, C. M. I. M., de Waart, D. R., van Gemert, W. G., Cleutjens, J. P. M., Gijbels, M. J., Shiri‐Sverdlov, R., Mookerjee, R. P., Lenaerts, K., et al. (2017) · Journal of Clinical and Translational Research · doi:10.18053/jctres.03.201703.004 · Cited by 9

Investigating intestinal farnesoid X receptor functions at the intestinal mucosal barrier and in the intestinal microbiota in a biliary obstruction mouse model

Cai, Y., Chen, X., Wang, H., Hou, L., Zheng, R., Wang, Y., Jiang, W., & Tang, W. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2024 · Cited by 4